Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Adagloxad simolenin + Cyclophosphamide + OBI-821|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Adagloxad simolenin||OPT-822|OBI 822|OBI822||Adagloxad simolenin (OBI-822) is an immunotherapy comprised of Globo H hexassaccharide 1 and keyhole limpet hemocyanin, which upon treatment, results in a cytotoxic T-cell response against cells expressing Globo H, and thus, may lead to antitumor activity (PMID: 32718986).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|OBI-821||OBI821|OBI 821||OBI-821 is a natural saponin derived from the soapbark tree, Quillaja saponaria Molina, which when combined with a vaccine may help promote a cytotoxic T-cell response against tumor cells (PMID: 32718986).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|